Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 2/20 | 0.34 |
| ▸ | CCNH | P51946 | 2/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CCNK | O75909 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495726 | 0.89 | CDK7 (0.36) | CDK7CCNHMNAT1MAPK8IKBKB | |
| SCHEMBL13638557 | 0.84 | IKBKB (0.45) | IKBKBCHUKIKBKGCDK2 | |
| SCHEMBL13638664 | 0.78 | IKBKB (0.33) | IKBKBCHUKIKBKG | |
| SCHEMBL13638665 | 0.78 | IKBKB (0.39) | IKBKBCHUKIKBKGCDK2 | |
| SCHEMBL13638661 | 0.77 | RPS6KB2 (0.38) | MAPK8 | |
| SCHEMBL13638417 | 0.77 | IKBKB (0.31) | IKBKBCHUKIKBKG | |
| SCHEMBL13638458 | 0.75 | IKBKB (0.36) | IKBKBCHUKIKBKGCCNE1CDK2 | |
| SCHEMBL13638500 | 0.72 | IKBKB (0.33) | IKBKBCHUKIKBKGCDK2 | |
| SCHEMBL13638456 | 0.72 | IKBKB (0.42) | IKBKBCHUKIKBKGCCNE1CDK2 | |
| SCHEMBL13638429 | 0.72 | IKBKB (0.34) | MAPK8IKBKBCHUKIKBKGCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | CDK7 207/4885CCNH 2043/4885MNAT1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.